The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).
Ramaprasad Srinivasan
Research Funding - GlaxoSmithKline
Donald P. Bottaro
Research Funding - GlaxoSmithKline
Toni K. Choueiri
Research Funding - GlaxoSmithKline
Ulka N. Vaishampayan
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jonathan E. Rosenberg
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Theodore Logan
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Andrea Lynne Harzstark
Research Funding - GlaxoSmithKline
Brian I. Rini
Research Funding - GlaxoSmithKline
Sandy Srinivas
Research Funding - GlaxoSmithKline
Laurel M. Adams
Employment or Leadership Position - GK Oncology R&D
Stock Ownership - GlaxoSmithKline
Kevin Laubscher
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Lone Harild Ottesen
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline (B)
David F. McDermott
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
W. Marston Linehan
Research Funding - GlaxoSmithKline